b

Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR




b

Bone Marrow Transplantation




b

NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma




b

Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells




b

The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors




b

QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism




b

WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2




b

LncRNA <i>SNORD3A</i> specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression




b

NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas




b

MicroRNA let-7c (MIRLET7C; let-7c), miR-99a and miR-125b as prognostic markers of luminal breast cancer

Studies in patient samples and cell culture suggest let-7c, miR-99a and miR-125b could serve as prognostic markers in patients with estrogen receptor–positive luminal breast cancers.




b

Chromosome 11 open reading frame 30 (C11orf30), calpain small subunit 1 (CAPNS1; CAPN4), signal transducer and activator of transcription 6 (STAT6) and ankyrin repeat domain 27 (ANKRD27) as diagnostic markers for eosinophilic esophagitis (EoE)

Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE.




b

RNAi against therapeutic targets with short interfering ribonucleic neutrals (siRNNs)

siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA.




b

Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent binding to neonatal Fc receptor

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives.




b

Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

Mouse studies suggest inhibiting PGF could help treat hypertension.




b

Topoisomerase II binding protein 1 (TOPBP1)

Mouse and cell culture studies suggest inhibiting TOPBP1 could help treat cancer.




b

Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4

Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines.




b

Epidermal growth factor receptor 1 (EGFR1; ErbB1; HER1); HER2 (EGFR2; ErbB2; neu); HER3 (EGFR3; ErbB3); VEGF

Tumor cell and mouse studies suggest tetravalent antibodies that target four different antigens could help treat cancers resistant to HER-targeted therapies.




b

Cyclin dependent kinase 7 (CDK7); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC)

In vitro and mouse studies suggest THZ1, a covalent CDK7 inhibitor, could help treat neuroblastoma and other cancers driven by MYCN and other c-MYC (MYC)-family oncoproteins.




b

Resurrecting a magic bullet

Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.




b

Translational tidbits

Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships.




b

Translational balance

Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.




b

SciBX: Science-Business eXchange




b

Pac1/LIS1 stabilizes an uninhibited conformation of dynein to coordinate its localization and activity




b

In vitro capture and characterization of embryonic rosette-stage pluripotency between naive and primed states




b

Bridging naïve and primed pluripotency




b

Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis




b

FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome




b

Nature Cell Biology




b

MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis




b

In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses




b

Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice




b

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials




b

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40




b

UNC5B mediates G2/M phase arrest of bladder cancer cells by binding to CDC14A and P53




b

High-purity orbital angular momentum states from a visible metasurface laser




b

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy




b

Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization




b

Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation




b

An in vitro Förster resonance energy transfer-based high-throughput screening assay identifies inhibitors of SUMOylation E2 Ubc9




b

Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy




b

Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy




b

Head-to-head trials in inflammatory bowel disease: past, present and future




b

Feeding back on ingestion




b

Microbiota and colorectal cancer: colibactin makes its mark




b

Colons or semi-colons: punctuating the regional variation of intestinal microbial–immune interactions




b

Universal screening for hepatitis C virus infection should be linked to universal treatment access




b

Author Correction: Management of IBD during the COVID-19 outbreak: resetting clinical priorities




b

A novel multidimensional reinforcement task in mice elucidates sex-specific behavioral strategies




b

Cannabinoid CB<sub>2</sub> receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear




b

A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology